(GHRS) – StreetInsider.com Reports
-
GH Research PLC (GHRS) PT Lowered to $39 at JMP Securities
-
GH Research (GHRS) Granted EU Parent for Mebufotenin and Mebufotenin Salt Products
-
GH Research PLC (GHRS) PT Lowered to $18 at Stifel
-
GH Research PLC (GHRS) PT Lowered to $30 at Canaccord Genuity
-
GH Research PLC (GHRS) Tops Q3 EPS by 9c
-
GH Research PLC (GHRS) PT Raised to $49 at JMP Securities
-
GH Research PLC (GHRS) PT Lowered to $35 at Canaccord Genuity
-
GH Research PLC (GHRS) PT Lowered to $25 at Stifel
-
EF Hutton Starts GH Research PLC (GHRS) at Buy
-
UPDATE: H.C. Wainwright Starts GH Research PLC (GHRS) at Buy
-
Roth Capital Starts GH Research PLC (GHRS) at Buy
-
GH Research PLC (GHRS) PT Lowered to $41 at Canaccord Genuity
-
GH Research PLC (GHRS) PT Lowered to $35 at Canaccord Genuity
-
GH Research (GHRS) Reports Q3 Net Loss of $1.8M, Cash Position of $280.7M, Issues Business Updates
-
GH Research (GHRS) Reports Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001
-
GH Research PLC (GHRS) PT Raised to $36 at JMP Securities
-
Canaccord Genuity Starts GH Research PLC (GHRS) at Buy
-
Cowen Starts GH Research PLC (GHRS) at Outperform
-
UPDATE: JMP Securities Starts GH Research PLC (GHRS) at Market Outperform
-
Stifel Starts GH Research PLC (GHRS) at Buy
-
GH Research PLC (GHRS) IPO Opens 38% Higher
Back to GHRS Stock Lookup